Booster with Ad26.COV2.S or Omicron-adapted vaccine enhanced immunity and efficacy against SARS-CoV-2 Omicron in macaquesLaura Solforosi(Janssen (Netherlands)), Frank Wegmann(Janssen (Netherlands))Nature CommunicationsApril 7, 202310.1038/s41467-023-37715-2Cited by 19SaveCiteExport RISWatch citationsRelated PapersEvaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)|The Lancet|2018|342Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study|The Lancet HIV|2020|91